GlassScriptPhysician profile
Eminajulo Adekoya
NPI 1497040208
$8,866.04
in general payments reported to CMS, 2019-2025
50 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.87 · 2021: $672 · 2022: $1,144 · 2023: $2,116 · 2024: $2,504 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,595 · Travel and Lodging: $371 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,595.45 |
| Travel and Lodging | $370.96 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,451.95 | 2022-2025 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $850.87 | 2021-2025 | Lithovue, Spaceoar System, General - Kidney Stone Disease |
| Sumitomo Pharma America, INC. | $679.50 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $587.98 | 2021-2025 | Botox, Lupron Depot |
| Calyxo, INC. | $541.18 | 2024-2025 | Cvac Aspiration System |
| Astellas Pharma US INC | $467.67 | 2021-2025 | Myrbetriq, Xtandi |
| Axonics, INC. | $401.16 | 2022-2024 | Axonics |
| Coloplast Corp | $285.62 | 2021-2024 | Speedicath |
| Merck Sharp & Dohme LLC | $284.26 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Myriad Genetic Laboratories, INC. | $280.77 | 2022-2025 | Prolaris |
| Endo USA, INC. | $247.38 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $233.34 | 2021-2025 | Jelmyto |
| Teleflex LLC | $227.55 | 2021-2025 | Urolift |
| Janssen Biotech, INC. | $189.82 | 2022-2025 | Erleada, Akeega |
| Myovant Sciences INC. | $164.68 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eminajulo Adekoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.